Utility of polaprezinc in reducing toxicities during radiotherapy: a literature review.

Abstract

Chemoradiotherapy is important for treating malignancies. However, radiation-induced toxicities develop as chemoradiotherapy-related complications. Various agents reduce or prevent toxicities, but there are no standard treatments. Polaprezinc (PZ), a chelating compound used for gastric ulcers, has antioxidant and free radical scavenging effects. Although few studies have evaluated PZ and radiation-induced normal tissue damage, several clinical studies have shown the efficacy of PZ for oral mucositis, esophagitis, proctitis and taste alterations during and after radiotherapy. Moreover, preclinical data support the clinical data, indicating good potential of testing PZ in future trials. However, as there are only few well-documented review articles on PZ use in cancer treatment, we conducted this literature review. PZ reduced several radiation-induced toxicities and improved the quality of life.

• Authors: Hiroshi Doi, Kozo Kuribayashi, Takashi Kijima
• Journal: Future oncology (London, England) (Future Oncol) Vol. 14 Issue 19 Pg. 1977-1988 (Aug 2018) ISSN: 1744-8301 [Electronic] England
• PMID: 30074413 (Publication Type: Journal Article, Review)

Chemical References

• Antioxidants
• Organometallic Compounds
• Zinc Compounds
• polaprezinc
• Zinc Sulfate
• Carnosine

Topics

• Abnormalities, Radiation-Induced (drug therapy, pathology)
• Antioxidants (therapeutic use)
• Carnosine (analogs & derivatives, therapeutic use)
• Humans
• Organometallic Compounds (therapeutic use)
• Quality of Life
• Radiation Injuries (drug therapy, pathology)
• Radiotherapy (adverse effects)
• Stomatitis (drug therapy, etiology, pathology)
• Zinc Compounds (therapeutic use)
• Zinc Sulfate (therapeutic use)